Definiens, Cernostics Team on Multiplex Cancer Tests | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Definiens and Cernostics today announced that they will collaborate on the development of multiplex molecular diagnostics tests for a variety of cancers.

Danville, Pa.-based Cernostics will use Definiens' Tissue Studio digital pathology technology to develop the tests. The Definiens technology enables pathologists to analyze cancers on the cellular and sub-cellular level, the firms said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.